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Background: Obesity has been associated with increased incidence of colorectal cancer. Adipose tissue dysfunction
accompanied with alterations in the release of adipocytokines has been proposed to contribute to cancer
pathogenesis and progression. The aim of this study was to analyze plasma concentrations of several adipose tissue
expressed hormones in colorectal cancer patients (CRC) and morbidly obese (MO) patients and to compare these
concentrations to clinicopathological parameters.
Methods: Plasma concentrations of adiponectin, resistin, leptin, active plasminogen activator inhibitor (PAI)-1,
monocyte chemotactic protein (MCP)-1, interleukin (IL)-1 alpha, and tumor necrosis factor (TNF)-alpha were
determined in 67 patients operated on for CRC (31 rectal cancers, 36 colon cancers), 37 patients operated on for
morbid obesity and 60 healthy blood donors (BD).
Results: Compared to BD, leptin concentrations were lowered in CRC patients whereas those of MO patients
were elevated. Adiponectin concentrations were only lowered in MO patients. Concentrations of MCP-1, PAI-1,
and IL-1 alpha were elevated in both CRC and MO patients, while resistin and TNF-alpha were similarly expressed
in MO and CRC patients compared to BD. Resistin concentrations positively correlated with tumor staging (p<0.002)
and grading (p=0.015) of rectal tumor patients.
Conclusions: The results suggest that both MO and CRC have low-grade inflammation as part of their etiology.
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Obesity is an increasing health problem not only for
industrialized countries but also for most other parts of
the world affecting all ages [1]. Besides the established
complications like cardiovascular disorders and type II
diabetes mellitus, obesity has not only been associated
with a 1.5–3.5-fold increased cancer incidence, but also
with increased cancer mortality, especially in morbidly
obese patients (BMI > 40 kg/m2) [2,3]. A positive associ-
ation between obesity and risks for cancers like endomet-
rial or kidney cancer is well documented [4-6]. There is
also an association between obesity and colorectal cancer,* Correspondence: Andreas.Hillenbrand@uniklinik-ulm.de
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distribution, and reproduction in any mediumhowever, this association appears to be stronger in males,
particularly with visceral adiposity and weaker and less
consistent in women, underlining gender-specific differ-
ences regarding the correlation of obesity and cancer de-
velopment [7-10].
A number of mechanisms have been proposed for the
adverse effect of obesity on colorectal cancer risk includ-
ing the distribution of body fat, alteration in hormonal
patterns, obesity-related inflammation, and metabolic dis-
turbances [11]. White adipose tissue has been increasingly
recognized as an important endocrine organ. The physio-
logical functions of adipose tissue are changed in obesity,
leading to an altered secretion of adipocytokines, which
may influence cancer pathogenesis and progression
[12,13]. These adipocytokines, particularly adiponectin,
leptin, tumor necrosis factor-alpha (TNF-α), and somentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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[14] may indicate an association between obesity and
colorectal cancer by influencing the obesity associated
low grade inflammation and the growth and prolifera-
tion of tumor stroma and malignant cells within [15-17].
Furthermore, interaction between tumor and stromal cells
may influence tumor progression. Tumor associated
macrophages, which are major components of stroma and
attracted by MCP-1, have been reported to play a role in
tumor progression [18].
Knowledge of the pathophysiological mechanisms of
these various protein signals underlying the association
between obesity and cancer origin may be important for
the development of preventive and therapeutic strategies
for malignancies. These proteins involved in various sig-
naling pathways are called adipocytokines. Hereafter, the
term adipokine refers to the adipose tissue expressed
hormones leptin, resistin and adiponectin and the term
cytokines refers to IL-1α and TNF-α. Monocyte chemo-
tactic protein-1 (MCP-1) is a chemokine, a protein that
acts as a chemical messenger, and active PAI-1 belongs
to the family of serine protease inhibitors. In literature
there are contradictory reports regarding adipokine con-
centrations in colorectal cancer patients [19]. Furthermore,
recent studies suggest that changes in the expression of
adipose tissue expressed hormones may reflect a mechan-
ism linking obesity to tumor genesis [20,21].
The aim of this study is, (i) to provide an adipokine
profile in three different groups (colorectal cancer patients,
morbidly obese patients and healthy blood donors), (ii) to
assess the influence of altered adipocytokine expression on
tumorigenesis, (iii) to investigate the association between
plasma adipokine concentrations and clinicopathological
characteristics of CRC and (iv) to demonstrate similari-
ties in the cytokine/chemokine profile of CRC and MO
patients. Our data indicate that MO and CRC have both
chronic low-grade inflammation as part of their etiology.Methods
Patients
The patients were divided into three subgroups: Sub-
group 1: patients with colorectal cancer (CRC); subgroup
2: morbidly obese (MO) patients; subgroup 3: healthy
blood donors (BD) as control group. Inclusion criteria to
participate voluntarily in the study were age >18 years,
no further malignant or rapidly progressing or hema-
tologic underlying disease, no HIV/AIDS, or cytotoxic
therapy given within the previous 6 months. The study
was performed with the permission of the independent
local ethics committee of the University of Ulm
(approvals 112/2003 and 73/2009). An informed consent
of all MO and CRC patients was obtained prior to sur-
gery in the author’s hospital.Fasting blood samples from CRC and MO patients
were collected preoperatively at 7 AM. Samples from BD
were taken at various times in a non-fasting state (10 ml
venous blood, collected in a chilled syringe with EDTA).
All samples were frozen in liquid nitrogen and stored in
the tissue bank of the Department of General and Visceral
Surgery of the University Hospital of Ulm, Germany.Cytokine and adipocyte expressed hormone
measurement and reagents
Multiplex analysis kits for IL-1α, TNF-α and Linco-Kit
human serum adipokine (panel A, panel B) for MCP-1, ac-
tive PAI-1, leptin, resistin and adiponectin were obtained
from Millipore, Hamburg, Germany. In brief, the appro-
priate cytokine standards and samples, diluted in plasma
dilution buffer, were added to wells of a filtered plate. The
samples were incubated with 50 μl of the antibody-
coupled microsphere set on a plate shaker in the dark at
room temperature for 30 min. The samples were washed
three times with 100 μl wash buffer. Freshly diluted
secondary detection antibody (25 μl/well) was added to
the wells and then incubated on a plate shaker in the dark
at room temperature. Thereafter, samples were washed
three times with 100 μl wash buffer. Fifty microliters of
strepavidin-PE (16 μg/ml in assay buffer) was added to
each well, and incubation continued on a plate shaker at
room temperature for the first 10 min. Unbound analytes
were filtered through the wells using the vacuum mani-
fold. The bound beads were washed three times with
100 μl wash buffer. After the last wash step, 125 μl of
assay buffer was added to each well and the plate was
placed on a plate shaker set at 500 rpm (G-force: 0.84 g)
for 1 min and then for 3 min at a reduced speed of
300 rpm (G-force: 0.30 g). Finally, samples were analyzed
on the Luminex system in accordance with the manufac-
turer’s instruction at the NMI of the University of Tübin-
gen. The lowest traceable value is according to the
sensitivity of the method 0.3 ng/ml for leptin and 9.2 pg/
ml for IL-1α. Intra-assay precision (Intra-CV%) and inter-
assay precision (Inter-CV%) are provided in Table 1.Statistical analysis
All values were expressed as median with range. Statistical
analysis was performed using WinSTAT software (Version
2009.1; R. FitchSoftware). Data were statistically analyzed
using the Mann–Whitney tests, and correlations between
the different adipocytokines by the non-parametic Spear-
man’s correlation test. The correlation coefficient is indi-
cated by r. Statistical significance was declared at p<0.05
and a tendency at 0.05<p<0.10. No adjustments were
made for multiple statistical comparisons.
Table 1 Median and range of adiponectin, resistin, leptin, active PAI-1, MCP-1, IL-1α and TNF-α plasma concentrations
of patients operated on for colorectal carcinoma (CRC) and morbid obesity (MO) as well as healthy blood donors (BD)
Parameters Intra-CV% Inter-CV% CRC (n=67) MO (n=37) BD (n=60) CRC vs. BD MO vs. BD CRC vs. MO
Adiponectin (μg/ml) 17.1 ↓9.4 14.7 n.s. p<0.001 p<0.001
3.9 / 7.8 (4.3 – 51.0) (3.8 – 57.8) (5.7 – 54.0)
Adiponectin females (μg/ml) 21.9 ↓12.4 22.5 n.s. p<0.001 p=0.002
(7.0 – 40.5) (5.3 – 57.8) (9.8 – 54.0)
Adiponectin males (μg/ml) 14.2 ↓8.3 11.8 n.s. p=0.001 p<0.001
(4.3 – 51.0) (3.8 – 12.3) (5.7 – 30.7)
Leptin (ng/ml) ↓2.6 ↑45.0 10.9 p<0.001 p<0.001 p<0.001
6.4 / 9.6 (0.3 – 33.3) (1.7 – 97.5) (0.3 – 58.5)
Leptin females ↓6.7 ↑47.3 15.8 p=0.011 p<0.001 p<0.001
(0.3 - 33.3) (16.1 – 97.5) (0.7 – 58.5)
Leptin males ↓1.7 ↑34.2 4.7 p=0.001 p<0.001 p<0.001
(0.3 – 19.6) (1.7 – 90.9) (0.3 – 19.1)
Resistin (ng/ml) 10.9 9.9 10.8 n.s. n.s. n.s.
8.3 / 11.1 (4.2 – 43.5) ( 3.7 – 83.6) (5.2 – 24.9)
MCP-1 (pg/ml) ↑127 ↑108 43.9 p<0.001 p<0.001 p=0.047
5.1 / 11.2 (22.7 – 451) (39.6 – 293) (12.1 – 150)
Active PAI-1 (ng/ml) ↑13.2 ↑57.5 6.0 p<0.001 p<0.001 p<0.001
17.4 / 20.0 (2.4 – 53.2) (3.7 – 176.7) ( 2.4 – 31.3)
TNF-α(pg/ml) 4.8 (n=63) 4.0 3.9 n.s. n.s. n.s.
9.4 / 10.7 (2.4 – 74.7) (2.4 – 26.8) ( 2.4 – 10.9)
IL-1α (pg/ml) ↑52.4 (n=63) ↑59.4 11.0 p<0.001 p<0.001 n.s.
20.0 / 35.7 (9.2 – 1322) (9.2 – 210.0) ( 9.2 – 168)
↓↑: Significantly elevated/lowered concentrations compared to BD.The inter- and intra-assay CVs are given below the corresponding parameters.
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Baseline characteristics of the study participants
Morbidly obese patients (24 female, 13 male) had a
median age of 45 years (range: 17 – 59) and a median BMI
of 52.0 kg/m2 (range: 33.5 – 78.0). The healthy BD
(30 female, 30 male) had a median age of 45 years (range:
19 – 71 years). Body mass index (BMI) was not ascertained
in this group. The CRC subgroup (25 female, 42 male)
included patients with colon cancer (36) and rectal cancer
(31). Median age of CRC patients was 66 years (range:
28 – 91 years), median BMI was 27.1 kg/m2 (range:
18.9 – 38.3). Rectal cancer was staged as stage I in 11, stage
II in 3, stage III in 11, and stage IV in 6 patients. Colon
cancer was staged as stage I in 8, stage II in 12, stage III in
12, and stage IV in 4 patients [22]. The BMIs of MO
patients were significantly higher compared to those of
CRC patients (p<0.01; WMU-T-Test). Gender-specific an-
thropometric data of all three groups are listed in Table 2.
Adipocytokine concentrations were clearly changed in
CRC and MO patients compared to healthy BD. For a
better overview, plasma concentrations of adiponectin,
resistin, leptin, active PAI-1, MCP-1, IL-1α, and TNF-α
and corresponding significant changes are shown inTable 1. A gender-specific difference was seen in the
values of adiponectin and leptin. In females, adiponectin
and leptin values were elevated compared to males.
Resistin, active PAI-1, MCP-1, IL-1α, and TNF-αshowed
no gender-specific differences.
Adipokines (adiponectin, resistin and leptin)
There was no significant gender-specific difference in adi-
ponectin concentrations in the CRC group compared to
the BD group, but, as expected, adiponectin was lowered
in the MO group (p<0.001 females and males). However,
significant differences in the plasma leptin concentrations
were detected in CRC patients compared to MO patients.
Leptin concentrations were significantly lowered in CRC
patients and significantly elevated in the MO compared to
the BD group (p≤0.01; Table 1). Resistin concentrations
showed no differences between the groups.
Plasma leptin concentrations in male patients with colon
carcinoma tended to be elevated compared to male patients
with rectal carcinoma (median leptin: 1.7 ng/ml; range:
0.3 – 19.6 ng/ml vs. 0.9 ng/ml; range: 0.3 – 6.7 ng/ml;
p=0.070). Females with colon/rectal cancer had comparable
leptin concentrations (6.3 ng/ml vs. 9.2 ng/ml; p=0.591;
Table 2 Gender-specific anthropometric data (age and BMI) of patients with colorectal cancer (CRC), morbid obesity
(MO) and healthy blood donors (BD)
Age [years] (median; range) BMI [kg/m2] (median; range)
CRC (n=67) 66.0 years (28 – 91) 27.1 kg/m2 (18.9 – 38.3)
Female patients (n=25) 66.0 years (28 – 91) 26.4 kg/m2 (18.9 – 35.5)
Male patients (n=42) 65.5 years (37 – 90) 27.2 kg/m2 (20.6 – 38.3)
Female rectal tumor patients (n=12) 64.5 years (41 – 84) 27.6 kg/m2 (18.9 – 35.5)
Male rectal tumor patients (n=19) 64.0 years (37 – 90) 27.2 kg/m2 (20.6 – 38.3)
Female colon tumor patients (n=13) 66.0 years (28 – 91) 26.3 kg/m2 (22.0 – 32.2)
Male colon tumor patients (n=23) 67.0 years (46 – 90) 26.8 kg/m2 (21.6 – 36.3)
MO (n=37) 45.0 years (17 – 59) 52.0 kg/m2 (33.5 – 78.0)
Female patients (n=24) 46.5 years (23 – 59) 52.4 kg/m2 (35.0 – 78.0)
Male patients (n=13) 42.0 years (17 – 59) 49.1 kg/m2 (33.5 – 70.4)
BD (n=60) 45.0 years (19 – 71) Not ascertained
Female control (n=30) 44.0 years (19 – 60) Not ascertained
Male control (n=30) 46.0 years (19 – 71) Not ascertained
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showed no difference in rectal and colon cancer groups (fe-
male rectal: 22.5 μg/ml; female colon: 21.9 μg/ml; male rec-
tal: 13.9 μg/ml; male colon 15.9 μg/ml). In all four
subgroups the BMI was not significantly different (female
colon/rectal: 26.4 kg/m2 vs. 27.6 kg/m2; male colon/rectal:
27.0 kg/m2 vs. 27.9 kg/m2). There was no significant differ-
ence in resistin concentrations among all patient groups.
Correlation of adipokines in colon cancer and rectal
cancer patients with tumor size based on T-staging and
tumor grading
In patients suffering from rectal carcinoma, resistin corre-
lates positively with tumor size based on T-staging [23]
(r=0.49; p<0.01) and tumor grading (r=0.39; p=0.02). If fo-
cused solely on males, this trend was even stronger (cor-
relation of resistin with T-staging in males: r=0.70; p<0.01;
correlation of resistin with tumor grading in males:
r=0.56; p<0.01). This effect was not seen in the female
subgroup (correlation of resistin with T-staging in females:
r=0.07; p=0.41; correlation of resistin with tumor grading
in females: r=0.13; p=0.34). However, after multivariate lo-
gistic regression with adjustment for age and gender there
was no significant correlation (Table 3). Possibly the loss
of significance could be due to the limited size of sub-
groups. In patients suffering from colon cancer, there was
no correlation of resistin concentrations with tumor size
based on T-staging and tumor grading. Plasma adiponec-
tin and leptin concentrations showed no correlation with
tumor size or tumor grading in colon or rectal cancer.
Monocyte chemotactic protein-1, active PAI-1, TNF-α, IL-1α
Monocyte chemotactic protein-1, active PAI-1, and IL-
1α were significantly elevated in CRC and MO patientscompared to BD controls whereas no significant changes
in TNF-αwere detected. However, it is striking that the
plasma concentrations in both MO and CRC patients
are changed in the same direction. Tumor necrosis
factor-α(TNF-α) and IL-1αplasma concentrations are
comparable in MO and CRC patients. In contrast, active
PAI-1 was higher in MO than CRC patients, and MCP-1
was higher in CRC than MO patients.
Discussion
The aim of this study was to demonstrate similarities in
the cytokine/chemokine profile of colorectal cancer
patients and morbidly obese since obesity is linked to an
increased risk of cancer [24] possibly due to adipose tis-
sue dysfunction accompanied with alterations in the re-
lease of adipocytokines. We found increased circulating
concentrations of MCP-1, PAI-1, and IL-1αin both CRC
and MO patients, while resistin and TNF-α were similarly
expressed in MO and CRC patients. Adiponectin concen-
trations were lowered only in MO patients, whereas leptin
concentrations were lowered in CRC patients.
Adipokines, in particular leptin and adiponectin, have
attracted much attention because of their potential role
in the development and progression of various obesity-
related malignancies [25,26]. We found lowered leptin
concentrations in CRC patients in agreement with other
studies [27]. Sălăgeanu and co-workers even report a
negative correlation between leptin and T-staging [19].
Interestingly, we found a significant difference in leptin
concentrations of male patients with colon carcinoma
vs. patients with rectal carcinoma. This difference was
not seen in female patients. Since both patient groups
have approximately the same BMI, this difference cannot
be explained by an obesity-related leptin elevation alone.
Figure 1 Leptin concentrations of CRC patients according to
tumor localization (colon cancer vs. rectal cancer). Male colon
cancer patients had (not significant) elevated leptin concentrations
compared to male rectal cancer patients (median colon cancer
leptin: 1.7 ng/ml; range: 0.3 – 19.6 ng/ml vs. median rectal cancer
leptin: 0.8 ng/ml; range: 0.3 – 6.7 ng/ml; p=0.062). There was no
difference in female patients (leptin: 9.2 ng/ml; range: 0.3 – 30.8 ng/
ml vs. median rectal cancer leptin: 6.3 ng/ml; range: 0.3 – 33.3 ng/
ml; p=0.07). The top and bottom of the rectangle represent the
25th and 75th percentile. The line within the rectangle represents
the median. The whiskers extend from the 5th percentile to the
95th percentile.
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concentrations in males was observed by Stattin and co-
workers [28]. Gender-specific concentrations were sig-
nificantly lowered in patients with CRC compared to the
control group. As suspected, leptin concentrations
showed a positive correlation to patients’ BMI.
Adiponectin may be a molecular marker for obesity
and CRC but evidence from large prospective studies
is limited [29]. Adiponectin is decreased in the obese
and is supposed to exert an anti-inflammatory and anti-
cancerous activity. Its absence is related to several
obesity-related malignancies including colorectal cancer
[30]. In several further studies, low plasma adiponectin
concentrations were an independent risk factor for colo-
rectal cancer and its precursory adenoma [31-33]. How-
ever, we report, as do others [34,35], no association
between plasma adiponectin concentration and CRC.
The association between adiponectin concentrations andTable 3 Correlation of resistin concentrations in rectal tumor
grading – multivariate logistic regression with adjustment fo
Variable Parameter p-value 95%-Confidence
Intercept 2.24 0.59 −6.28
Age 0.09 0.13 −0.03
Gender 1.93 0.22 −1.24
Grade 1.06 0.67 −4.04
Stage 2.11 0.19 −1.09the risk of colorectal cancer still remains controversial,
especially as there are different fractions of adiponectin
(total/high molecular weight/non-high molecular weight
adiponectin) with different hypothesized biological activ-
ities [29].
Resistin, a protein with proinflammatory properties, is
mainly expressed from macrophages rather than adipo-
cytes [36]. We observed similar resistin concentrations
in both CRC and MO. Resistin correlates positively with
tumor size based on T-staging and tumor grading. How-
ever, no significant results after adjustment for age and
gender could be observed by multivariate logistic regres-
sion due to the small number of cases. Further studies
found resistin being significantly elevated in cancer
patients and in several studies stage progression signifi-
cantly correlates with resistin concentrations [37,38]. We
found this trend to be stronger in males and only in
rectal cancer and not in colon cancer. In most other
studies, there is neither a gender specific differentiation
nor one between colon and rectal cancer [27,38].
Tumor necrosis factor-α(TNF-α) is a key cytokine, not
secreted by adipocytes but produced by both macro-
phages and malignant cells [39,40]. Expression and
secretion of TNF-α increase with obesity and correlate
positively with body mass index [41]. Several studies
suggest that TNF-α is involved in obesity-related insulin
resistance and that TNF-α is one of the most important
mediators of inflammation [42]. We found a slight but
not significant elevation of TNF-α in CRC patients com-
pared to MO and BD.
Plasminogen activator inhibitor-1 (PAI-1), a physio-
logical inhibitor of urokinase-type and tissue-type plas-
minogen activator, is an integral part of the fibrinolytic
system and contributes to the process of tumor invasion
and metastasis due to degrading of the cellular matrix
[43,44]. It was shown that plasma PAI-1 concentrations
correlated with metastatic disease in CRC patients [45]
and with the outcome of rectal cancer [46]. We also
found significantly elevated PAI-1 concentrations in
CRC patients as well as in MO compared to BD as con-
trol group.
Monocyte chemotactic protein-1 (MCP-1) is a chemo-
kine that accumulates and influences tumor associated
macrophages. This accumulation of macrophages seemspatients with tumor size based on T-staging and tumor
r age and gender
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either growth promotion or growth inhibition depending
upon the particular setting [47]. The presence of the in-
filtrating macrophages has been shown to correlate with
cancer metastasis and poor prognosis in a variety of
human carcinomas [48]. The expression of MCP-1 has
been reported in several tumors including human colo-
rectal cancer [49,50]. We found elevated concentrations
in MO as well as in CRC patients.
Interleukin-1 is a major mediator of inflammation and
is known to be up-regulated in many tumor types and
has been implicated as a factor in tumor progression
[51]. Interleukin-1 consists of two molecular species,
IL-1α and IL-1β, both of which exert similar biological
functions through the IL-1 type I receptor [52]. As in
cancer, elevated IL-1 concentrations are reported in
obesity [17]. Since macrophages accumulate in both tis-
sues, in adipose tissue in MO and cancer tissue in CRC
patients, elevated IL-1α concentrations are unsurprising
in both our groups.
Examining these cytokines, it is striking that plasma
concentrations of MO and CRC are changed in the same
direction. The amplitude of change of MO and CRC to
BD is comparable in TNF-α and IL-1α plasma concen-
trations. Active PAI-1 is proportionally more elevated in
MO compared to CRC. Monocyte chemotactic protein-
1, however, is proportionally more elevated in CRC com-
pared to MO. This could be explained by the fact that
PAI-1 is not only produced by the visceral adipose tissue
(increased in the morbidly obese) but also by steatotic
liver tissue in morbidly obese patients [53,54]. Monocyte
chemotactic protein-1 is produced by cancer cells and
multiple different host cells within the tumor micro-
environment and serves as one of the key mediators of
interactions between tumor and host cells [55]. Similar
cytokine/chemokines/PAI-1 profile in MO and CRC
patients reflects the obesity and tumor associated chro-
nic inflammation. However, the specific influence of adi-
pokines on tumor development and progression is still
not fully understood and has to be addressed.
Our study has several strengths and limitations. All
patients were recruited and operated on in the same
hospital. Blood samples of all three groups were col-
lected via the same protocol, were simultaneously stored,
and processed with the same assay. Patients of the MO
group were not only overweight, but truly morbidly
obese (median BMI of MO patients: 52.0 kg/m2). In the
absence of standard values for many adipocytokines we
provide a profile for the three different groups.
The main limitation of our study is the missing BMI
of the BD group due to the fact that in general body
weight and height are not routinely measured in the
Institute of Clinical Transfusion Medicine and Immuno-
genetics. This obviously affects the interpretation of theresults. Further limitations are the small sample size and
the associated lack of significance in statistical analysis
of the data and the lack of correlation of resistin levels
with tumor size based on T-staging and tumor grading
in patients suffering from colon cancer. Further, no
information was collected regarding a screening colon-
oscopy for colorectal cancer in the BD group.Conclusion
The aim of this study was to demonstrate similarities in
the cytokine/chemokine profile of colorectal cancer
patients and morbidly obese since obesity is linked to an
increased risk of cancer, possibly due to adipose tissue
dysfunction. We demonstrated similarities in the cyto-
kine/chemokine profile of CRC and MO patients. We
found significantly lowered leptin concentrations (gen-
der dependent) in the carcinoma group compared to
BD. In male patients with colon carcinoma, we report
elevated leptin concentrations compared to leptin con-
centrations in rectal tumor patients. Further, we found a
positive correlation of resistin and tumor size based on
T-staging in CRC males. Similarities in the cytokine/che-
mokine profile of colorectal cancer patients and the
morbidly obese indicate that both have chronic low-
grade inflammation as part of their etiology. Future
studies are warranted to confirm these results and to
elucidate the underlying mechanisms.
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